Charles L. Shapiro, MD

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

IBIS II is a prevention study in over 3,000 women who were randomized to anastrozole vs placebo

Anastrozole proved to be 50% effective in presenting breast cancer, primarily ER+ breast cancer, compared to the placebo

There was only a 10% difference in the grades of musculoskeletal arthralgias when comparing anastrozole to the placebo

Articles

Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Charles L. Shapiro, MD | Authors

Articles

The Results of the IBIS II Trial